After Many Delays, Highly Anticipated Mixed-Use Project May Be Moving Forward

Regent Square
Courtesy Of GID Development

The long-awaited mixed-use project at Regent Square just south of Allen Parkway is finally getting some traction. After being delayed for years, Morris Architects told the Houston Business Journal building permits should be secured by Q3. 10 architects are working on the project for Boston-based developer GID. HKS, Ziegler Cooper, CBT Architects and the Office of James Burnett are all involved. Harvey Builders is the general contractor.

Regent Square is planning to have roughly 400k SF of shops and restaurant space, 240k SF of office space and 950 multifamily units. One apartment building, the Sovereign, is already complete. The walkable community is along Buffalo Bayou at Dunlavy and West Dallas.

The project was originally supposed to break ground in 2013, before the oil crash, and it's been about to restart before. When the project is completed, Regent Square will be home to an Alamo Drafthouse in the heart of the city. [HBJ]

Continue reading this story with a free account

Log in or register
Sign up for more articles like this
Subscribe to Bisnow's Houston Newsletters
Related Stories

Cross Ocean Partners, Fuller Realty Acquire 829K SF Houston Office Campus

Trammell Crow Starts Phase Of 2M SF Industrial Park: The Houston Deal Sheet

Oncology Company Expands Footprint At Hines' Life Sciences Campus

Astrodome Conservancy Solicits Redevelopment Ideas

Food And Beverage Increasingly Becoming Anchor In Mixed-Use Projects

Sugar Land Town Square Secures Fortune 500 Lease: The Houston Deal Sheet

Houston CRE Firms Turn To Contractors As They Look To Scale

The Revitalization Of Sugar Creek On The Lake, A Premier Waterfront Property In Greater Houston

City Block Sold For New Houston Center Parking Garage

Beacon Partners Sells Charlotte Mixed-Use Development For $92M

Texas Pauses Data Center Power Connections, Which Could Speed Up Rapid Development

Houston's Generation Park Lands Another $2.3B Pharma Manufacturing Investment